Table 3. Comparison of adverse events between the experimental and control group.

Adverse events	Experimental group No. of patients (n)	Control group No. of patients (n)	Analysis method	Heterogeneity		Odds ratio (OR)	95% CI	P-value
				I2 (%)	P-value
Gastrointestinal adverse effects	691	680	Fixed	0	0.77	0.22	0.16–0.31	<0.00001
Leukopenia	491	455	Fixed	30	0.15	0.23	0.16–0.32	<0.00001
Thrombocytopenia	443	423	Random	65	0.0008	0.31	0.17–0.57	0.0001
Hepatotoxicity	604	575	Fixed	0	0.46	0.34	0.23–0.50	<0.00001
Nephrotoxicity	107	87	Fixed	Not applicable		0.64	0.27–1.47	0.29
Cardiotoxicity	147	143	Fixed	0	0.93	0.23	0.08–0.66	0.006
Hematotoxicity	408	404	Fixed	0	0.88	0.28	0.16–0.51	<0.0001
Myelosuppression	320	276	Fixed	0	0.65	0.47	0.28–0.81	0.006
Nausea and vomiting	382	352	Fixed	50	0.05	0.50	0.35–0.71	0.0001
Anemia	131	111	Fixed	0	0.41	0.53	0.30–0.94	0.03
Diarrhea	108	89	Fixed	0	0.65	0.59	0.32–1.10	0.10
Alopecia	122	119	Fixed	39	0.19	0.68	0.37–1.24	0.21
Neurotoxicity	100	96	Random	58	0.09	0.52	0.20–1.38	0.19

Notes: Control group, Conventional treatments alone group; Experimental group, Conventional treatments and Aidi injection combined group.